RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression
Our findings demonstrate that RPL28 contributes to sorafenib resistance in HCC by upregulating CDC6, contributing to tumor proliferation and drug resistance. The newly identified RPL28-CDC6 axis represents a novel mechanism of resistance and a potential therapeutic target to overcome treatment limitations in HCC.
Authors
- Yuanyuan Weng
- Yi Shi
- Fangfang Chen
- Gang Chen
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fonc.2026.1741406
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00